SLC5A2 and hydrops fetalis: The EMPEROR-Reduced and DAPA-HF studies demonstrated that SGLT2 inhibitors benefited HFrEF along with a reduction in CV death and/or hospitalisation for HF in both diabetic and non-diabetic patients (Colombo et al., 2020; Packer et al., 2020).